



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 10

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-004747US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DK	686	6,972,127	12-06-2005	Schenk	
	679	2005/0255122 A1	11-17-2005	Schenk	
	680	2005/0249727 A1	11-10-2005	Schenk	
	674	6,962,707	11-08-2005	Schenk	
	656	6,946,135	09-20-2005	Schenk	
	693	2005/0191314 A1	09-01-2005	Schenk	
	713	6,936,698	08-30-2005	Taylor	
	716	6,933,368	08-23-2005	Co et al.	
	758	2005/0169925 A1	08-04-2005	Bardroff et al.	
	685	2005/0163788 A1	07-28-2005	Schenk	
	657	6,913,745	07-05-2005	Schenk	
	715	2005/0136054 A1	06-23-2005	Adair et al.	
	658	6,905,686	06-14-2005	Schenk	
	714	2005/0123534 A1	06-09-2005	Adair et al.	
	659	6,890,535	05-10-2005	Schenk	
	683	2005/0059802 A1	03-17-2005	Schenk et al.	
	684	2005/0059591 A1	03-17-2005	Schenk et al.	
	661	2005/0009150 A1	01-13-2005	Basi et al.	
	673	6,808,712	10-26-2004	Schenk	
	667	6,787,523	09-07-2004	Schenk	
	670	6,787,144	09-07-2004	Schenk	
	668	6,787,143	09-07-2004	Schenk	
	672	6,787,140	09-07-2004	Schenk	
	669	6,787,138	09-07-2004	Schenk	
	671	6,787,129	09-07-2004	Schenk	
	660	2004/0171815 A1	09-02-2004	Schenk et al.	
	708	2003/0039645 A1	10-14-2003	Adair et al.	
	675	6,710,226	02-23-2004	Schenk	
	712	6,639,055	10-28-2003	Carter et al.	
	709	6,632,927	10-14-2003	Adair et al.	

Examiner
Signature

/Daniel Kolker/ (09/26/2006)

Date
Considered

09/26/2006

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60849503

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 10

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-004747US

DK	748	6,610,493	08-26-2003	Citron et al.	
	730	2003/0166557 A1	09-04-2003	Minna et al.	
	702	6,548,640	04-15-2003	Winter	
	725	6,538,124	03-25-2003	Idusogie et al.	
	726	6,528,624	03-04-2003	Idusogie et al.	
	710	6,407,213	06-18-2002	Carter et al.	
	720	6,277,375	08-21-2001	Ward	
	724	6,194,551	02-27-2001	Idusogie et al.	
	704	6,180,370	01-30-2001	Queen et al.	
	747	6,175,057	01-16-2001	Mucke et al.	
	719	6,165,745	12-26-2000	Ward et al.	
	723	6,121,022	09-19-2000	Presta et al.	
	722	5,869,046	02-09-1999	Presta et al.	
	707	5,859,205	01-12-1999	Adair et al.	
	770	5,733,548	03-31-1998	Restifo et al.	
	642	5,702,906	12-30-1997	Rosenthal	
	643	5,693,762	12-02-1997	Queen et al.	
	705	5,693,761	12-02-1997	Queen et al.	
	721	5,677,425	10-14-1997	Bodmer et al.	
	717	5,648,260	07-15-1997	Winter et al.	
	718	5,624,821	04-29-1997	Winter et al.	
	644	5,618,920	04-08-1997	Robinson et al.	
	764	5,601,827	02-11-1997	Collier et al.	
	706	5,585,089	12-17-1996	Queen et al.	
	619	5,530,101	06-25-1996	Queen et al.	
	645	5,258,498	11-02-1993	Huston et al.	
	703	5,225,539	07-06-1993	Winter	
	740	4,883,666	11-28-1989	Sabel et al.	
	646	4,816,567	03-28-1989	Cabilly et al.	
	647	4,816,397	03-28-1989	Boss et al.	

Examiner
Signature

/Daniel Kolker/ (09/26/2006)

Date
Considered

09/26/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

60849503

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 10

Complete if Known

Application Number 10/828,548
Filing Date April 19, 2004
First Named Inventor Schenk
Art Unit 1649
Examiner Name Kolker, D. E.
Attorney Docket Number 15270J-004747US

U.S. PATENT APPLICATIONS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DK	691	11/245,524	10-07-2005	Schenk	
	692	11/245,916	10-07-2005	Schenk	
	763	60/067,740	12-02-1997	Schenk	
	760	60/067,219	12-03-1997	Weiner et al.	
	761	60/079,697	03-27-1998	Weiner et al.	
	762	60/080,970	01-11-1999	Schenk	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
DK	738	EP	626 390	A1	11-30-1994			
DK	737	EP	620 276	A1	10-19-1994			
	692	JP	07-192093	A	05-23-1995			abst. only
	631	JP	62-267207	A	11-10-1987			abst. only
DK	701	WO	05/014041	A2	02-17-2005			
	757	WO	04/108895	A2, A3	12-16-2004			
	756	WO	03/016467	A2, A3	02-27-2003			
	772	WO	99/10008	A1	03-04-1999			
	633	WO	96/08665	A2	03-21-1996			
	630	WO	95/17085	A1	06-29-1995			
	690	WO	95/00407	A1	03-03-1995			
DK	736	WO	94/10569	A1	05-11-1994			
DK	648	WO	91/09967	A1	07-11-1991			

Examiner
Signature

/Daniel Kolker/ (09/26/2006)

Date
Considered

09/26/2006

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60849503

X IFW DID NOT RECEIVE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 11

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-004747US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DK	663	ALBERTS et al., eds. <i>Molecular Biology of The Cell, Third Edition</i> , chapter 23, pages 1208-1209 (1994).	
	773	ALBERTS ET AL., <i>Molecular Biology of the Cell, 2nd Edition</i> , pages 266-267, Garland Publishing Inc., New York (1989).	
	649	AMIT et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <i>Science</i> , 233:747-753 (1986).	
	588	ANDERSON, J. P., "Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells," <i>Neuroscience Letters</i> , 128(1):126-128 (1991).	
	589	ANDERSON, M. W., "Amending the amyloid hypothesis," <i>The Scientist</i> , 18(20):28-29 (2004).	
	677	ANKARCRONA et al., "Biomarkers for apoptosis in Alzheimer's disease," <i>Int. J. Geriatric Psychiatry</i> , 20:101-105 (2005).	
	681	AULD et al., "Alzheimer's disease and the basal forebrain cholinergic system: relations to β -amyloid peptides, cognition, and treatment strategies," <i>Progress in Neurobiol.</i> , 68:209-245 (2002).	
	590	BACSKAI et al., "Non-Fc-mediated mechanisms are involved in clearance of amyloid- β in vivo by immunotherapy," <i>J. Neurosci.</i> , 22(18):7873-7878 (2002).	
	750	BICKEL et al., "Development and in Vitro Characterization of a Cationized Monoclonal Antibody against β A4 Protein: A Potential Probe for Alzheimer's Disease," <i>Bioconjugate Chem.</i> , 5:119-125 (1994).	
	754	BLASBERG et al., "Regional Localization of Glioma-associated Antigen Defined by Monoclonal Antibody 81C6 in Vivo: Kinetics and Implications for Diagnosis and Therapy," <i>Cancer Research</i> , 47:4432-4443 (1987).	✓
	746	BRAZIL et al., "Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia," <i>J. Biol. Chem.</i> , 275(22):16941-16947 (2000).	✓
✓	639	Chimicon International, "Mouse Anti-Amyloid Beta Protein Monoclonal Antibody," Catalog # MAB1561 NO DATE	

Examiner
Signature

/Daniel Kolker/ (09/26/2006)

Date
Considered

09/26/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60849503 -----44631-1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 11

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-004747US

DK	591	CHROMY et al., "Self-assembly of A β (1-42) into globular neurotoxins," <u>Biochemistry</u> , 42(44):12749-12760 (2003).	
	592	CITRON et al., "Evidence that the 42- and 40- amino acid forms of amyloid- β protein are generated from the β -amyloid precursor protein by different protease activities," <u>PNAS</u> , 93(23):13170-13175 (1996).	
	593	CITRON, M., "Alzheimer's disease: treatments in discovery and development," <u>Nat. Neurosci.</u> , 5:1055-1057 (2002).	
	699	CLAYTON et al., "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," <u>J. Neurosci. Res.</u> , 58:120-129 (1999).	
	766	COICO et al., <u>Immunology A Short Course, Fifth Edition</u> , pages 18-24 (2003).	✓
	687	COX et al., "Adjuvants—a classification and review of their modes of action," <u>Vaccine</u> , 15(3):248-256 (1997).	
	769	DAVIS, S. S., "Nasal Vaccines," <u>Advanced Drug Delivery Reviews</u> , 51:21-42 (2001).	
	689	DE LUSTIG et al., "Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations," <u>Rev. In Neurosciences</u> , 5:213-225 (1994).	
	594	DEMATTOS et al., "Brain to plasma amyloid- β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease," <u>Science</u> , 295(5563):2264-2267 (2002).	
	745	DEWITT et al., "Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease," <u>Experimental Neurology</u> , 149:329-340 (1998).	
	698	Dictionary.com definition of "prophylactic", pages 1-3 downloaded from internet 10/12/05.	
	735	DI MARTINO et al., "Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-carrier Linked Synthetic Peptide Immunogens," <u>J. Molecular Recognition</u> , 4(2-3):85-91 (1991).	
	595	DODART et al., "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model," <u>Nat. Neurosci.</u> , 5(5):452-457 (2002).	
	596	DODEL et al., "Immunotherapy for Alzheimer's disease," <u>Lancet Neurol.</u> , 2(4):215-220 (2003).	
✓	597	DOVEY et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <u>J. Neurochem.</u> , 76(1):173-181 (2001).	

Examiner
Signature

/Daniel Kolker/ (09/26/2006)

Date
Considered

09/26/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60849503 ---44631-1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

6

of

11

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-004747US

DK	598	DUFF et al., "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1," <u>Nature</u> , 383(6602):710-713 (1996).	
	599	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo," <u>J. Clin. Invest.</u> , 112(3):440-449 (2003).	
	600	FINDEIS, M. A., "Approaches to discovery and characterization of inhibitors of amyloid β -peptide polymerization," <u>Biochem. Biophys. Acta</u> , 1502(1):76-84 (2000).	
	650	FOOTE et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <u>J. Mol. Biol.</u> , 224:487-499 (1992).	
	601	FRENKEL et al., "Reduction of β -amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization," <u>Vaccine</u> , 21(11-12):1060-1065 (2003).	
	602	FRENKEL et al., "Towards Alzheimer's β -amyloid vaccination," <u>Biologicals</u> , 29(3-4):243-247 (2001).	
	603	GELINAS et al., "Immunotherapy for Alzheimer's disease," <u>PNAS</u> , 101(suppl. 2):14657-14662 (2004).	
	634	Genbank Accession number AAB48800, "Anti-DNA immunoglobulin light chain IgG [Mus musculus]," 09/14/01.	
	635	Genbank Accession number CAA46659, "IgE antibody light chain(VJ)," 06/15/93.	
	636	Genbank Accession number X65775.1, "M.musculus DNA for IgE antibody light chain (VJ)," 06/15/93.	
	637	Genbank Accession number AAD26773, "Immunoglobulin heavy chain VH3609-JH3 region [Mus musculus]," 04/22/99.	
	604	GONG et al., "Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss," <u>PNAS</u> , 100(18):10417-10422 (2003).	
	605	GREENBERG et al., "Alzheimer disease's double-edged vaccine," <u>Nat. Med.</u> , 9(4):389-390 (2003).	
	694	GUPTA et al., "Adjuvants for human vaccines—current status, problems, and future prospects," <u>Vaccine</u> , 13(14):1263-1275 (1995).	
	606	HAASS, C., "New hope for Alzheimer disease vaccine," <u>Nat Med.</u> , 8(11):1195-1196 (2002).	

Examiner
Signature

/Daniel Kolker/ (09/26/2006)

Date
Considered

09/26/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60849503 —44631-1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/828,548
				Filing Date	April 19, 2004
				First Named Inventor	Schenk
				Art Unit	1649
				Examiner Name	Kolker, D. E.
Sheet	7	of	11	Attorney Docket Number	15270J-004747US

DK	664	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 71-82 (1998).	
	741	HIRSCHFIELD et al., "Amyloidosis: new strategies for treatment," <i>Int. J. Biochem. & Cell Biol.</i> , 35:1608-1613 (2003).	
	607	HOCK et al., "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease," <i>Nat. Med.</i> , 8(11):1270-1275 (2002).	
	662	IDA et al., "Analysis of Heterogeneous β A4 Peptides in Juman Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay," <i>J. Biol. Chem.</i> , 271(37):22908-22914 (1996).	
	608	IRIZARRY et al., "Alzheimer disease therapeutics," <i>J. Neuropathol. Exp. Neurol.</i> , 60(10):923-928 (2001).	
	609	JANUS et al., "Transgenic mouse models of Alzheimer's Disease," <i>Physiol. Behav.</i> , 73(5):873-886 (2001).	
	640	JUNG et al., "Alzheimer's Beta-amyloid Precursor Protein Is Expressed on the Surface of Immediately Ex Vivo Brain Cells: a Flow Cytometric Study," <i>J. Neurosci. Res.</i> , 46:336-348 (1996).	
	729	KASCSAK et al., "Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins," <i>J. Virology</i> , 61(12):3688-3693 (1987).	
	628	KOFLER et al., "Mechanism of Allergic Cross-Reactions—III. cDNA Cloning and Variable-Region Sequence Analysis of Two IgE Antibodies Specific for Trinitrophenyl," <i>Mol. Immunology</i> , 29(2):161-166 (1992).	
	627	KRISHNAN et al., "Correlation Between the Amino Acid Position of Arginine in VH-CDR3 and Specificity for Native DNA Among Autoimmune Antibodies ^{1,2} ," <i>J. Immunol.</i> , 157(6):2430-2439 (1996).	
	695	KÜO et al., "Water-soluble A β (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," <i>J. Biol. Chem.</i> , 271(8):4077-4081 (1996).	
	734	KURASHIMA et al., "Production of Monoclonal Antibody against Amyloid Fibril Protein and Its Immunohistochemical Application," <i>Appl. Pathol.</i> , 3(1-2):39-54 (1985).	
	651	LANDOLFI et al., "The Integrity of the Ball-and Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody," <i>J. Immunology</i> , 166(3):1748-1754 (2001).	
↓	755	LAVIE et al., "EFRH-Phage Immunization of Alzheimer's Disease Animal Model Improves Behavioral Performance in Morris Water Maze Trials," <i>J. Molecular Neuroscience</i> , 24:105-113 (2004).	✓

Examiner Signature	/Daniel Kolker/ (09/26/2006)	Date Considered	09/26/2006
--------------------	------------------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60849503 —44631-1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/828,548
		Filing Date	April 19, 2004
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
		Attorney Docket Number	15270J-004747US
Sheet	8	of	11

DK	743	LICASTRO et al., "Is immunotherapy an effective treatment for Alzheimer's disease?," <u>Immunity & Aging</u> , 1:1-2 (2004).	
	727	LINKE, "Monoclonal antibodies against amyloid fibril protein AA. Production, specificity, and use for immunohistochemical localization and classification of AA-type amyloidosis," <u>J. Histochemistry and Cytochemistry</u> , 32(3):322-328 (1982).	
	665	LO et al., "High level expression and secretion of Fc-X fusion proteins in mammalian cells," <u>Protein Engineering</u> , 11(6):495-500 (1998).	
	666	MANDEL et al., "Clinical trials in neurological disorders using AAV vectors: promises and challenges," <u>Curr. Opin. Mol. Ther.</u> , 6(5):482-490 (2004).	
	742	MANOJ et al., "Approaches to Enhance the Efficacy of DNA Vaccines," <u>Critical Rev. Clin. Lab. Sci.</u> , 41(1):1-39 (2004).	
	731	MARHAUG et al., "Monoclonal hybridoma antibodies to human amyloid related protein SAA," <u>Clin. Exp. Immunol.</u> , 50(2):390-396 (1982).	
	744	MAROTTA et al., "Overexpression of amyloid precursor protein A4 (β -amyloid) immunoreactivity in genetically transformed cells: Implications for a cellular model of Alzheimer amyloidosis," <u>PNAS</u> , 86:337-341 (1989).	
	610	MATTSON et al., "Good and bad amyloid antibodies," <u>Science</u> , 301(5641):1845-1849 (2003).	
	732	MAURY et al., "Immunohistochemical Localization of Amyloid in Finnish Hereditary Amyloidosis with Antibodies to Gelsolin Peptides," <u>Laboratory Investigation</u> , 64(3):400-404 (1991).	
	611	MCLAURIN et al., "Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues and 4-10 and inhibit cytotoxicity and fibrillogenesis," <u>Nat Med.</u> , 8(11):1263-1269 (2002).	
	612	MONSONEGO et al., "Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer's disease," <u>J. Clin. Invest.</u> , 112(3):415-422 (2003).	
	613	MONSONEGO et al., "Immunotherapeutic approaches to Alzheimer's disease," <u>Science</u> , 302(5646):834-838 (2003).	
	652	ORLANDI et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <u>PNAS</u> , 86:3833-3837 (1989).	
↓	614	PAGANETTI et al., "Amyloid precursor protein truncated at any of the γ -secretase sites is not cleaved to β -amyloid," <u>J. Neurosci. Res.</u> , 46(3):283-293 (1996).	

Examiner Signature	/Daniel Kolker/ (09/26/2006)	Date Considered	09/26/2006
--------------------	------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60849503 ---44631-1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 9 of 11

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-004747US

DK	615	PALLITTO et al., "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity," <u>Biochemistry</u> , 38(12):3570-3578 (1999).	
	654	PANKA et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <u>PNAS</u> , 85:3080-3084 (1998).	
	682	PARNETTI et al., "Cognitive Enhancement Therapy for Alzheimer's Disease, The Way Forward," <u>Drugs</u> , 53(5):752-768 (1997).	
	653	PAUL, W. E., eds., <i>Fundamental Immunology</i> , Third Edition, pages 292-295, Raven Press, New York (1993).	
	774	PEETERS et al., "Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates," <u>J. Immunological Methods</u> , 120:133-143 (1989).	/
	616	PFEIFER et al., "Cerebral hemorrhage after passive anti-A β immunotherapy," <u>Science</u> , 298(5597):1379 (2002).	
	733	PHELPS et al., "Development and Characterization of Monoclonal Antibodies Specific for Amylin," <u>Hybridoma</u> , 15(5):379-386 (1996).	
	751	PROBERT et al., "Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α ," <u>PNAS</u> , 92:11294-11298 (1995).	/
	641	RACKE et al., "Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of amyloid β ," <u>J. Neurosci.</u> , 25(3):629-636 (2005).	
	638	Research Corporation Technology News, "THP and SangStat Partner to Develop Humanized Polyclonal Antibody Drugs," 11/11/02.	
	626	"Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice," downloaded from www.businesswire.com on 12/15/04.	
	655	RUDIHOFF et al., "Single amino acid substitution altering antigen-binding specificity," <u>PNAS</u> , 79:1979-1983 (1982).	
	617	SCHMID, R. E., "Study suggest Alzheimer vaccine fix," from www.msnbc.com/news, pages 1-5 (2002).	
↓	768	SCHMITT et al., "Interactions of the alzheimer β amyloid fragment ₍₂₅₋₃₅₎ with peripheral blood dendritic cells," <u>Mechanisms of Ageing and Development</u> , 94:223-232 (1997).	/

Examiner
Signature

/Daniel Kolker/ (09/26/2006)

Date
Considered

09/26/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60849503 ---44631-1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 10 of 11

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-004747US

DK	629	SEIDL et al., "Predominant V _H genes expressed in innate antibodies are associated with distinctive antigen-binding sites," <u>PNAS</u> , 96:2262-2267 (1999).	
	618	SELKOE, D. J., "Alzheimer's disease is a synaptic failure," <u>Science</u> , 298(5594):789-791 (2002).	
	622	SERGEANT et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <u>J. Neurochem.</u> , 85(6):1581-1591 (2003).	
	697	SMALL et al., "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," <u>PNAS</u> , 97(11):6037-6042 (2000).	
	620	SOLOMON, B., "Generation and brain delivery of anti-aggregating antibodies against β -amyloid plaques using phage display technology," <u>J. Neural Transm. Suppl.</u> , 62:321-325 (2002).	
	621	SOLOMON, B., "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease," <u>DNA and Cell Biology</u> , 20(11):697-703 (2001).	
	678	SOUDER et al., "Overview of Alzheimer's disease," <u>Nurs. Clin. N. Am.</u> , 39:545-559 (2004).	
	767	TRIEB et al., "APP Peptides Stimulate Lymphocyte Proliferation in Normals, But Not in Patients With Alzheimer's Disease," <u>Neurobiology of Aging</u> , 17(4):541-547 (1996).	
	700	VALLEIX et al., "Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family," <u>Kidney International</u> , 61:907-912 (2002).	
	775	VAN DEN DOBBELSTEEN et al., "Characteristics of Immune Responses to Native and Protein Conjugated Pneumococcal Polysaccharide Type 14," <u>Scand. J. Immunol.</u> , 41:273-280 (1995).	✓
	690	VICKERS, J. C., "A Vaccine Against Alzheimer's Disease," <u>Drugs Aging</u> , 19(7):487-494 (2002).	
	623	WALSH et al., "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo," <u>Nature</u> , 416(6880):535-539 (2002).	
	624	WASHINGTON UNIVERSITY IN ST. LOUIS SCHOOL OF MEDICINE, "Study gives Clues to Working of Anti-Alzheimer Antibody," downloaded from www.medicine.wustl.edu/~wumpa/news on 12/15/04.	
	676	Webster's New World Dictionary, page 1387, therapeutic (1988).	
✓	688	Webster's New World Dictionary of American English, Third College Edition, page 1078 (1988).	

Examiner
Signature

/Daniel Kolker/ (09/26/2006)

Date
Considered

09/26/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60849503 ----44631-1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 11

of 11

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-004747US

DK	765	WEINER, H. L., "Oral tolerance: immune mechanisms and treatment of autoimmune diseases," <u>Immunology Today</u> , 18:335-343 (1997).	✓
	739	WEINREB et al., "NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded," <u>Biochemistry</u> , 35(43):13709-13715 (1996).	
	625	WHITE et al., "Immunotherapy as a therapeutic treatment for neurodegenerative disorders," <u>J. Neurochem.</u> , 87(4):801-808 (2003).	
	749	Wikipedia definition of "epitope" printed from internet on 4/26/06.	
	752	Wikipedia definition of "antigen" printed from internet on 4/26/06.	✓
	753	Wikipedia definition of "route of administration including parenteral" printed from internet on 4/26/06.	✓
↓	728	YAMADA et al., "Generation and Characterization of Rat Monoclonal Antibodies Against Human Serum Amyloid A," <u>Scand. J. Immunol.</u> , 46(2):175-179 (1997).	

Examiner
Signature

Daniel Kolker/ (09/26/2006)

Date
Considered

09/26/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60849503 ----44631-1